Track Tango Therapeutics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Tango Therapeutics Inc. TNGX · Stock Open Tango Therapeutics Inc. in new tab

25.50 USD
EPS
-1.38
P/B
4.06
ROE
-36.48
Beta
1.22
Target Price
46.64 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-1.38
Book Value5.79
Price to Book4.06
Debt/Equity3.18
% Insiders1.187%
Growth
Revenue Growth-1.00%
Estimates
Forward P/E-13.12
Forward EPS-1.79
Target Mean Price46.64

DCF valuation

Model fair value for Tango Therapeutics Inc. (TNGX)
Result
Sign in to run the valuation for TNGX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Strong buy · mean target 46.64 USD (low 24.00, high 69.00) · as of 10 Nov 2026
Low 24.00
Mean 46.64
High 69.00
Price 25.50
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Tango Therapeutics Inc. Logo Tango Therapeutics Inc. Analysis (TNGX)

United States Health Care Official Website Stock

Is Tango Therapeutics Inc. a good investment? Tango Therapeutics Inc. (TNGX) is currently trading at 25.50 USD. Market analysts have a consensus price target of 46.64 USD. This suggests a potential upside from current levels.

Earnings Schedule: Tango Therapeutics Inc. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -1.79.

Investor FAQ

Does Tango Therapeutics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Tango Therapeutics Inc.?

Tango Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -1.38.

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Exchange Ticker
NMS (United States) TNGX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion